The US FDA has approved telisotuzumab vedotin for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer. It is indicated specifically for NSCLC patients with high c-Met protein overexpression who have received prior systemic therapy.
Clinical evidence In a clinical trial involving 84 adult patients, telisotuzumab vedotin achieved a 35% overall response rate with a median duration of response of 7.2 months. Dosage and administration Available for intravenous infusion Administer intravenously (1.9 mg/kg) every two weeks until disease progression or unacceptable toxicity Contraindications – None Warnings and precautions Peripheral neuropathy Interstitial lung disease/pneumonitis Ocular surface disorders Infusion-related reactions Embryo-fetal toxicity Adverse reactions Peripheral neuropathy, fatigue, decreased appetite, and peripheral…
